CTLA4 and neoplasm: The triple combination of anti‐PD‐1, anti‐RANKL and anti‐CTLA‐4 antibodies was more efficacious in suppression of CT26 s.c. growth than with any dual therapy, consistent with our previous report using hybridoma mAbs.15 Similarly, the addition of anti‐RANKL/PD‐1 BsAb to anti‐CTLA4 suppressed tumor growth of CT26 tumor‐bearing mice and resulted in a significantly greater anti‐tumor efficacy than any dual combination therapy tested (Figure 6).